{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:10:35Z","timestamp":1790511035878,"version":"4.1.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) and chimeric antigen receptor T cell (CAR T) therapy are the main modalities of adoptive cellular immunotherapy that have widely permeated the clinical space. The advent of both technologies revolutionized treatment of many hematologic malignancies, both offering the chance at sustained remissions for patients who would otherwise invariably succumb to their diseases. The understanding and exploitation of the nonspecific alloreactivity of allo-HCT and the graft-versus-tumor effect is contrasted by the genetically engineered precision of CAR T therapy. Historically, those with relapsed and refractory hematologic malignancies have often been considered for allo-HCT, although outcomes vary dramatically and are associated with potential acute and chronic toxicities. Such patients, mainly with B-lymphoid malignancies, may now be offered CAR T therapy. Yet, a lack of prospective data to guide decisions thereafter requires individualized approaches on whether to proceed to allo-HCT or observe. The continued innovations to make CAR T therapy more effective and accessible will continue to alter such approaches, but similar innovations in allo-HCT will likely result in similarly improved clinical outcomes. In this review, we describe the history of the two platforms, dissect the clinical indications emphasizing their intertwining and competitive roles described in trials and practice guidelines, and highlight innovations in which they complement or inform one another.<\/jats:p>","DOI":"10.3389\/fonc.2020.608916","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T08:24:12Z","timestamp":1608625452000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?"],"prefix":"10.3389","volume":"10","author":[{"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone-Marrow Transplantation","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-Marrow Transplantation","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301206","article-title":"Bone Marrow Transplantation","volume":"330","author":"Armitage","year":"1994","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078166","article-title":"Hematopoietic-Cell Transplantation at 50","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724.Supported","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2015","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cgt.2014.81","article-title":"Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies","volume":"22","author":"Wang","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02037","article-title":"Clinical cancer advances 2019: Annual report on progress against cancer from the American society of clinical oncology","volume":"37","author":"Pal","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.003","article-title":"Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not","volume":"26","author":"Bouziana","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better","volume":"34","author":"D\u2019Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1052808","article-title":"When to recommend allogeneic transplant in multiple myeloma","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1148\/58.6.863","article-title":"Modification of Acute Irradiation Injury in Mice and Guinea-Pigs by Bone Marrow Injections","volume":"58","author":"Lorenz","year":"1952","journal-title":"Radiology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(96)90004-1","article-title":"The history of bone-marrow transplantation","volume":"10","author":"Perry","year":"1996","journal-title":"Blood Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217","article-title":"The Graft-Versus-Leukemia Effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.22","article-title":"Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future","volume":"52","author":"Saad","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.11.520","article-title":"Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions","volume":"12","author":"Huff","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.exphem.2012.09.008","article-title":"Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience","volume":"41","author":"El-Cheikh","year":"2013","journal-title":"Exp Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.blre.2012.11.002","article-title":"Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom","volume":"27","author":"Chang","year":"2013","journal-title":"Blood Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-445098","article-title":"Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis","volume":"121","author":"Gupta","year":"2013","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current Use of and Trends in Hematopoietic Cell Transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834f5c41","article-title":"Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults","volume":"24","author":"Khaled","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin\u2019s Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"TPS7573","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7573","article-title":"ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory\/relapsed follicular lymphoma (r\/r FL)","volume":"37","author":"Dickinson","year":"2019","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality","volume":"32","author":"Fenske","year":"2013","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705904","article-title":"Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia","volume":"41","author":"Fielding","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine\/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation","volume":"128","author":"Lee III","year":"2016","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2019","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)\u2013an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed\/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London England)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.410","article-title":"Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial","volume":"25","author":"Grupp","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/asheducation-2018.1.16","article-title":"Are CAR T cells better than antibody or HCT therapy in B-ALL","volume":"2018","author":"Pulsipher","year":"2018","journal-title":"Hematology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood-2018-99-115599","article-title":"Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission","volume":"132","author":"Summers","year":"2018","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01985","article-title":"Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes","volume":"11","author":"Schultz","year":"2020","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0604-3","article-title":"The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia","volume":"54","author":"Jacoby","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clml.2015.02.024","article-title":"Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades","volume":"15","author":"Bhatt","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1050.bloodjournal8441050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed\/Refractory (R\/R) Large B Cell Lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Large B-Cell Lymphoma: Real World Experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood-2019-124364","article-title":"Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs","volume":"134","author":"Kilgore","year":"2019","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1283036","article-title":"Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop","volume":"58","author":"Kahl","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B91","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001843","article-title":"The case for CAR T-cell therapy in follicular lymphomas","volume":"134","author":"Bishop","year":"2019","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Ot\u00e1hal","year":"2016","journal-title":"Oncoimmunology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-2","article-title":"Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Kharfan-Dabaja","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.173","article-title":"Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment","volume":"48","author":"Armeson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.026","article-title":"Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability","volume":"18","author":"Patriarca","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.187","article-title":"Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation","volume":"49","author":"Freytes","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.278","article-title":"CS1 Targeted Chimeric Antigen Receptors (CAR) for treatment of multiple myeloma (MM)","volume":"19","author":"O\u2019Neal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02756.x","article-title":"Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia","volume":"113","author":"Matthews","year":"2001","journal-title":"Br J Haematol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12425","article-title":"Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study","volume":"162","author":"Shah","year":"2013","journal-title":"Br J Haematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208751","article-title":"Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality","volume":"104","author":"Cummins","year":"2019","journal-title":"Haematologica"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e000845","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","article-title":"Treating Relapsed\/Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-762419","article-title":"Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia","volume":"129","author":"Godwin","year":"2017","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004791","article-title":"A bispecific approach to improving CAR T cells in AML","volume":"135","author":"Daver","year":"2020","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.006668","article-title":"Mouse models of graft-versus-host disease: advances and limitations","volume":"4","author":"Schroeder","year":"2011","journal-title":"Dis Model Mech"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/nri2200","article-title":"Specificity of T-cell alloreactivity","volume":"7","author":"Felix","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337","article-title":"Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.jcyt.2019.03.569","article-title":"CD19 chimeric antigen receptor (CAR) engineered epstein-barr virus (EBV) specific T cells \u2013 an off-the-shelf, allogeneic CAR T-cell immunotherapy platform","volume":"21","author":"Shen","year":"2019","journal-title":"Cytotherapy"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.353.353","article-title":"CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT","volume":"120","author":"Curran","year":"2012","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.608916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T08:24:15Z","timestamp":1608625455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.608916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":154,"alternative-id":["10.3389\/fonc.2020.608916"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.608916","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"article-number":"608916"}}